What is Hoth Therapeutics Inc's earnings per share (EPS)?

Hoth Therapeutics Inc (HOTH) reported diluted earnings per share of $-0.90 for fiscal year 2025. This represents a 29.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Hoth Therapeutics Inc Financials

HOTH

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows Hoth Therapeutics Inc (HOTH) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI HOTH FY2025 2026-05-15

Hoth is functioning as a cash-funded development program, with equity financing refilling losses in place of operating inflows.

Per-share optics improved in FY2025 even though net loss deepened to $12.5M from $8.2M. That apparent improvement is consistent with share dilution, not operating progress: the share base nearly doubled, and financing cash inflow of $9.3M almost replaced the year's operating cash burn.

FY2025's heavier burn was not just a noncash accounting move: operating cash outflow widened to $9.8M as both R&D and SG&A rose, reversing the leaner pattern seen in FY2024. That mix suggests the company advanced programs and corporate overhead together, so cash needs were driven by spending choices rather than a temporary working-capital swing.

The balance sheet still looks lightly leveraged, with debt-to-equity at 0.2x and a current ratio of 4.7x. But that liquidity is thinner than those ratios imply because year-end cash of $6.2M sat below one year of operating cash burn, making external funding part of the operating model.

Financial Health Signals

Financial Profile 32/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Hoth Therapeutics Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

Hoth Therapeutics Inc carries a low D/E ratio of 0.24, meaning only $0.24 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 97/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

With a current ratio of 4.72, Hoth Therapeutics Inc holds $4.72 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 94/100.

Returns

Hoth Therapeutics Inc generates a -202.7% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -119.0% the prior year.

Piotroski F-Score Weak

1/9

Hoth Therapeutics Inc passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

0.79x

For every $1 of reported earnings, Hoth Therapeutics Inc generates $0.79 in operating cash flow (-$9.8M OCF vs -$12.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

-$12.5M

YoY-52.3%

Hoth Therapeutics Inc reported -$12.5M in net income in fiscal year 2025. This represents a decrease of 52.3% from the prior year.

EPS (Diluted)

$-0.90

YoY+29.7%

Hoth Therapeutics Inc earned $-0.90 per diluted share (EPS) in fiscal year 2025. This represents an increase of 29.7% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$6.2M

YoY-11.2%

5Y CAGR+18.9%

Hoth Therapeutics Inc held $6.2M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

16M

YoY+92.9%

Hoth Therapeutics Inc had 16M shares outstanding in fiscal year 2025. This represents an increase of 92.9% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-202.7%

YoY-83.7pp

5Y CAGR-47.8pp

Hoth Therapeutics Inc's ROE was -202.7% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 83.7 percentage points from the prior year.

Capital Allocation

R&D Spending

$5.9M

YoY+83.0%

5Y CAGR+21.1%

Hoth Therapeutics Inc invested $5.9M in research and development in fiscal year 2025. This represents an increase of 83.0% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

HOTH Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$5.9M+83.0%	$3.2M-13.1%	$3.7M-24.1%	$4.9M-33.0%	$7.4M+222.4%	$2.3M
SG&A Expenses	$6.4M+29.2%	$5.0M+17.9%	$4.2M-31.3%	$6.1M	N/A	N/A
Operating Income	-$12.4M-50.5%	-$8.2M-3.3%	-$8.0M+28.1%	-$11.1M+21.5%	-$14.1M-93.1%	-$7.3M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$12.5M-52.3%	-$8.2M-1.0%	-$8.1M+28.7%	-$11.4M+20.6%	-$14.3M-98.9%	-$7.2M
EPS (Diluted)	$-0.90+29.7%	$-1.28+46.2%	$-2.38	$-9.50+40.7%	$-16.02	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$1.5M	N/A	$1.6M+57.1%	$1.0M-46.9%	$2.0M	N/A	$994K+54.4%	$644K
SG&A Expenses	$1.1M	N/A	$2.4M+111.0%	$1.2M-23.6%	$1.5M	N/A	$1.2M+14.4%	$1.1M
Operating Income	-$2.6M	N/A	-$4.1M-85.5%	-$2.2M+36.7%	-$3.5M	N/A	-$2.2M-29.3%	-$1.7M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$2.7M	N/A	-$4.1M-86.7%	-$2.2M+36.7%	-$3.5M	N/A	-$2.2M-30.3%	-$1.7M
EPS (Diluted)	$-0.17	N/A	$-0.30-76.5%	$-0.17+37.0%	$-0.27	N/A	$-0.32-28.0%	$-0.25

HOTH Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$7.6M-1.4%	$7.7M-24.7%	$10.2M+32.3%	$7.7M-29.5%	$11.0M+109.5%	$5.2M
Current Assets	$6.9M-10.2%	$7.6M-24.7%	$10.2M+31.7%	$7.7M-27.1%	$10.6M+121.1%	$4.8M
Cash & Equivalents	$6.2M-11.2%	$7.0M-24.3%	$9.3M+44.5%	$6.4M-24.7%	$8.5M+224.7%	$2.6M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$1.5M+74.2%	$834K+18.3%	$705K-57.0%	$1.6M+48.5%	$1.1M+84.7%	$597K
Current Liabilities	$1.5M+74.8%	$831K+22.5%	$679K-51.1%	$1.4M+59.9%	$868K+178.0%	$312K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$6.2M-10.6%	$6.9M-27.9%	$9.5M+56.2%	$6.1M-38.2%	$9.9M+112.7%	$4.6M
Retained Earnings	-$72.9M-20.6%	-$60.4M-15.7%	-$52.2M-18.4%	-$44.1M-4585.6%	$983K+105.1%	-$19.4M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$5.6M-26.4%	$7.6M-17.8%	$9.2M-8.5%	$10.1M-18.2%	$12.4M+60.2%	$7.7M-11.9%	$8.7M-17.2%	$10.6M
Current Assets	$4.9M-29.2%	$6.9M-23.1%	$8.9M-11.3%	$10.1M-18.2%	$12.3M+60.8%	$7.6M-11.9%	$8.7M-17.3%	$10.5M
Cash & Equivalents	$4.0M-35.2%	$6.2M-20.4%	$7.8M-12.9%	$9.0M-20.4%	$11.3M+60.8%	$7.0M-12.0%	$8.0M-17.1%	$9.7M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$1.4M-1.4%	$1.5M+43.4%	$1.0M+177.7%	$365K-55.3%	$815K-2.2%	$834K+2.6%	$813K+17.5%	$692K
Current Liabilities	$1.4M-1.4%	$1.5M+43.4%	$1.0M+177.7%	$365K-55.3%	$815K-1.9%	$831K+2.6%	$810K+19.0%	$681K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$4.2M-32.3%	$6.2M-25.3%	$8.2M-15.5%	$9.7M-15.6%	$11.5M+67.8%	$6.9M-13.3%	$7.9M-19.7%	$9.9M
Retained Earnings	-$75.6M-3.7%	-$72.9M-3.8%	-$70.2M-6.2%	-$66.1M-3.4%	-$63.9M-5.8%	-$60.4M-3.6%	-$58.3M-4.0%	-$56.1M

HOTH Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$9.8M-40.5%	-$7.0M+17.4%	-$8.4M+9.2%	-$9.3M+23.1%	-$12.1M-97.1%	-$6.1M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	-$300K	N/A	N/A	$1.2M+802.5%	-$165K+91.0%	-$1.8M
Financing Cash Flow	$9.3M+96.3%	$4.7M-58.1%	$11.3M+87.5%	$6.0M-66.8%	$18.2M+108.5%	$8.7M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$3.1M-41.9%	-$2.2M+13.7%	-$2.5M-5.1%	-$2.4M+14.9%	-$2.8M-37.5%	-$2.0M-24.1%	-$1.6M-2.7%	-$1.6M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	$147K	$0	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$701K+27.5%	$550K-66.2%	$1.6M+2362.1%	$66K-99.1%	$7.1M+566.2%	$1.1M	$0	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

HOTH Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-202.7%-83.7pp	-119.0%-34.0pp	-85.0%+101.3pp	-186.3%-41.4pp	-144.8%+10.1pp	-154.9%
Return on Assets	-164.0%-57.8pp	-106.2%-27.0pp	-79.1%+67.7pp	-146.9%-16.6pp	-130.3%+7.0pp	-137.3%
Current Ratio	4.72-4.5	9.20-5.8	14.96+9.4	5.56-6.6	12.19-3.1	15.32
Debt-to-Equity	0.24+0.1	0.12+0.0	0.07-0.2	0.27+0.2	0.11-0.0	0.13
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-64.7%	N/A	-49.9%-27.3pp	-22.6%+7.6pp	-30.1%	N/A	-28.1%-10.8pp	-17.3%
Return on Assets	-48.1%	N/A	-44.4%-22.7pp	-21.8%+6.4pp	-28.1%	N/A	-25.5%-9.3pp	-16.2%
Current Ratio	3.39-1.3	4.72-4.1	8.81-18.8	27.57+12.5	15.08+5.9	9.20-1.5	10.71-4.7	15.41
Debt-to-Equity	0.34+0.1	0.24+0.1	0.12+0.1	0.04-0.0	0.07-0.1	0.12+0.0	0.10+0.0	0.07
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Lisata Therapeutics Inc LSTA

$29.1M

Elevation Oncolo ELEV

$21.6M

Q32 BIO INC QTTB

$120.2M

Curis CRIS

$19.3M

Passage Bio, Inc. PASG

$17.8M

Frequently Asked Questions

Is Hoth Therapeutics Inc profitable?

No, Hoth Therapeutics Inc (HOTH) reported a net income of -$12.5M in fiscal year 2025.

What is Hoth Therapeutics Inc's return on equity (ROE)?

Hoth Therapeutics Inc (HOTH) has a return on equity of -202.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Hoth Therapeutics Inc's operating cash flow?

Hoth Therapeutics Inc (HOTH) generated -$9.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Hoth Therapeutics Inc's total assets?

Hoth Therapeutics Inc (HOTH) had $7.6M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Hoth Therapeutics Inc spend on research and development?

Hoth Therapeutics Inc (HOTH) invested $5.9M in research and development during fiscal year 2025.

How many shares does Hoth Therapeutics Inc have outstanding?

Hoth Therapeutics Inc (HOTH) had 16M shares outstanding as of fiscal year 2025.

What is Hoth Therapeutics Inc's current ratio?

Hoth Therapeutics Inc (HOTH) had a current ratio of 4.72 as of fiscal year 2025, which is generally considered healthy.

What is Hoth Therapeutics Inc's debt-to-equity ratio?

Hoth Therapeutics Inc (HOTH) had a debt-to-equity ratio of 0.24 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Hoth Therapeutics Inc's return on assets (ROA)?

Hoth Therapeutics Inc (HOTH) had a return on assets of -164.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Hoth Therapeutics Inc's cash runway?

Based on fiscal year 2025 data, Hoth Therapeutics Inc (HOTH) had $6.2M in cash against an annual operating cash burn of $9.8M. This gives an estimated cash runway of approximately 8 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Hoth Therapeutics Inc's Piotroski F-Score?

Hoth Therapeutics Inc (HOTH) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Hoth Therapeutics Inc's earnings high quality?

Hoth Therapeutics Inc (HOTH) has an earnings quality ratio of 0.79x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Hoth Therapeutics Inc?

Hoth Therapeutics Inc (HOTH) scores 32 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.